71381-75-4

Basic information

• Product Name: 1-BOC-PIPERIDINE-3-CARBOXYLIC ACID
• Synonyms: BOC-DL-NIP-OH;BOC-DL-NIPC-OH;BOC-DL-NIPECOTIC ACID;BOC-DL-PIC(3)-OH;BOC-3-CARBOXYPIPERIDINE;BOC-NIP;BOC-NIP-OH;BOC-(R,S)-NIP-OH
• CAS NO: 71381-75-4
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Mol File: 71381-75-4.mol
• Article Data: 42

Chemical Properties

• Melting Point: 159-162 °C(lit.)
• Appearance: /
• CAS DataBase Reference: 1-BOC-PIPERIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-PIPERIDINE-3-CARBOXYLIC ACID(71381-75-4)
• EPA Substance Registry System: 1-BOC-PIPERIDINE-3-CARBOXYLIC ACID(71381-75-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 71381-75-4(Hazardous Substances Data)

Usage

General Description

1-BOC-piperidine-3-carboxylic acid, also known as tert-Butyl 3-piperidinecarboxylate, is a type of organic compound. It is commonly used as a chemical reagent in organic synthesis, due to its role as a building block in the creation of a variety of complex molecules. This chemical has a molecular formula of C11H19NO3, featuring a piperidine ring which is a common feature in many biologically active compounds. Additionally, it is usually found as a colorless liquid or solid in its physical form. Safety measures should be adhered to when handling this substance as it may cause skin and eye irritation, and even serious eye damage.

Upstream product

• 498-95-3 nipecotic acid 
• 59-67-6 nicotinic acid 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 
• 851956-01-9 (S)-(+)-3-piperidinecarboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 123-91-1 1,4-dioxane 
• 121-44-8 triethylamine 
• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 71962-74-8 Ethyl nipecotate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 

Downstream Products

• 744221-50-9 3-(4-hexyloxy-benzylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 676259-95-3 piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-(2,6-diisopropyl-phenyl) ester 
• 798576-73-5 N-(tert-butyloxycarbonyl)piperidine-3-carboxylic acid [1(S)-(3,4-dibenzyloxy-5-oxo-2,5-dihydrofuran-2(R)-yl)-2-bromoethyl] ester 
• 479080-28-9 tert-butyl 3-[amino(hydroxyimino)methyl]piperidine-1-carboxylate 
• 940868-22-4 tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate 
• 91419-53-3 (+/-)-2-N-tert-butoxycabonylpiperidine-3-carbonitrile 

Relevant articles and documents

Design, Synthesis and Enhanced BBB Penetration Studies of L-serine-Tethered Nipecotic Acid-Prodrug

Nipecotic acid is considered to be one of the most potent inhibitors of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Due to its hydrophilic nature, nipecotic acid does not readily cross the blood-brain barrier (BBB). Large neutral amino acids (LAT1)-knotted nipecotic acid prodrug was designed and synthesized with the aim to enhance the BBB permeation by the use of carrier-mediated transport. The synthesized prodrug was tested in animal models of Pentylenetetrazole (PTZ)-induced convulsions in mice. Further pain studies were carried out followed by neurotoxicity estimation by writhing and rota-rod test respectively. HPLC data suggests that the synthesized prodrug has improved penetration through BBB. Nipecotic acid-L-serine ester prodrug with considerable anti-epileptic activity, and the ability to permeate the BBB has been successfully synthesized. Graphical Abstract. Graphical Abstract.

NAPHTHO[2,1 -D]THIAZOLE DERIVATIVES, COMPOSITIONS THEREOF AND METHODS OF TREATING DISORDERS

The present application relates to the compounds of formula (I) that inhibit CDK9, pharmaceutical compositions thereof and methods of making and using the same.

SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY

In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.